NCT00693485

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.

Conditions

• Glaucoma, Open-Angle

Interventions

Type	Name	Description
DRUG	400 ug Brimonidine Implant	400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
DRUG	200 ug Brimonidine Implant	200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
DRUG	Sham (no implant)	Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

Timeline

• Start date: 2008-09-01
• Primary completion: 2011-01-01
• Completion: 2011-08-01
• First posted: 2008-06-09
• Last updated: 2013-04-24
• Results posted: 2013-04-24

Locations

2 sites across 2 countries: United States, Israel